Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Background treatment Clear all
Completed Phase 4 Interventional

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

NCT03635125
View directory record Official record
Conditions
JNC 7 Stage 1 or 2 Hypertension
Interventions
Nebivolol I, Nebivolol II, Baseline Washout Phase
Drug · Other
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthier You: Optimizing Screening, Brief Interventions, and Referral to Treatment (SBIRT) in the Emergency Department

NCT01113190
View directory record Official record
Conditions
Drug Abuse
Interventions
Computer-delivered Brief Intervention (CBI), Intervener-delivered Brief Intervention (IBI), Adapted Motivational Enhancement Therapy (AMET), Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
878 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 2 Interventional Results available

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

NCT00902486
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
INCB028050, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 28, 2026, 8:22 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

NCT00424294
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-195,543, celecoxib, Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
39
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Upland, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 28, 2026, 8:22 PM EDT
Completed No phase listed Observational

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

NCT00115505
View directory record Official record
Conditions
Breast Carcinoma
Interventions
quality-of-life assessment, Questionnaire Administration
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
227
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Fresno, California + 154 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 28, 2026, 8:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 28, 2026, 8:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685
View directory record Official record
Conditions
Alport Syndrome
Interventions
BAY 3401016, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 3 Interventional Results available

A Moderate to Severe Rheumatoid Arthritis Study

NCT01721044
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Baricitinib, cDMARD
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 28, 2026, 8:22 PM EDT
Withdrawn Phase 2 Interventional

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

NCT05641298
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Sodium Fusidate, Placebo
Drug
Lead sponsor
Aceragen
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
25
States / cities
Gainesville, Florida • Orlando, Florida • Pensacola, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Early Phase 1 Interventional

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

NCT03232164
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasm
Interventions
18F-DCFPyL PET
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 28, 2026, 8:22 PM EDT
Completed No phase listed Observational

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

NCT03843593
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Demographics Questionnaire, Adjuvant Treatment Beliefs Scale10, Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13, Decisional Regret14, Clinician Preference for Treatment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

NCT02580552
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype, Adult T-Cell Leukemia/Lymphoma (ATLL)
Interventions
Cobomarsen
Drug
Lead sponsor
miRagen Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 28, 2026, 8:22 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
109
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT04460885
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 4 Interventional Results available

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

NCT00756730
View directory record Official record
Conditions
HIV Infections
Interventions
ATV/r, DRV/r
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 28, 2026, 8:22 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437
View directory record Official record
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
84
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

NCT03175367
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 28, 2026, 8:22 PM EDT
Completed No phase listed Observational Results available

Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

NCT05061095
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Assessment Surveys, Qualitative Interviews
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
51 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

NCT02885181
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GS-9876, Filgotinib, GS-9876 placebo, Filgotinib placebo, Methotrexate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
DeBary, Florida • Sarasota, Florida • Canton, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
60
States / cities
Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

NCT01819129
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, Insulin aspart, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
77
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Music Practical Examinations

NCT06187272
View directory record Official record
Conditions
Test Anxiety, Stress
Interventions
Listening to music
Behavioral
Lead sponsor
Russell Sage College
Other
Eligibility
19 Years to 34 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 28, 2026, 8:22 PM EDT
Active, not recruiting Not applicable Interventional

A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases

NCT05341739
View directory record Official record
Conditions
Brain Metastases, Adult
Interventions
Pre-operative Stereotactic Radiosurgery
Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 28, 2026, 8:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 28, 2026, 8:22 PM EDT